Aura Biosciences, Inc.
AURAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. With a market capitalization of $784.0M, it sits in small-cap territory. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Market Cap
$784.0M
Beta
0.40
P/E (TTM)
—
P/E (Fwd)
-3.72
EPS (TTM)
$-1.73
EPS (Fwd)
$-2.03
ROE
-53.5%
ROA
-31.2%
Cash
$323.8M
Total Debt
$16.6M
Free CF
-$56.3M
52W Change
17.0%
Annual Financials
Cash vs Debt
Where AURA stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, AURA finished 13.07% above its 150-day moving average ($6.81) and 17.74% above its 200-day moving average ($6.54). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AURA overbought or oversold?
At the August 28, 2026 close, AURA's RSI(14) was 43.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $323.8M in cash comfortably exceeding the $16.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$56.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -53.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Aura Biosciences, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, AURA has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Aura Biosciences, Inc.'s trajectory.